A link to the Executable paper challenge and my slides can be found here: 
http://www.w3.org/wiki/HCLSIG/SWANSIOC/Actions/RhetoricalStructure/meetings/20110620
 

Best, 

- Anita.  

Anita de Waard
Disruptive Technologies Director, Elsevier Labs
http://elsatglabs.com/labs/anita/
a.dewa...@elsevier.com



-----Original Message-----
From: Tim Clark [mailto:tim_cl...@harvard.edu]
Sent: Sun 6/19/2011 11:25
To: HCLS IG
Cc: Alberto Accomazzi; Sophia Ananiadou; Philip Bourne; Gully Burns; Daniel, 
Ronald (ELS-SDG); Rahul Dave; Waard, Anita de A (ELS-AMS); Alf Eaton; Alexander 
Garcia Castro; Matthew Gamble; Yolanda Gil; Alyssa Goodman; Paul Groth; Tudor 
Groza; Hays, Ellen (ELS-BUR); Maryann Martone; David R Newman; Scerri, Antony 
(ELS-CAM); Jack Park; Silvio Peroni; Steve Pettifer; Philippe Rocca-Serra; 
Cartic Ramakrishnan; Jodi Schneider; David Shotton; Kaitlin Thaney; Karin 
Verspoor; Lynette Hirschman; Susanna-Assunta Sansone; Kees van Bochove; Katy 
Wolstencroft; Jun Zhao
Subject: Reminder - Scientific Discourse concall Mon., 20 Jun 2011, 10am EDT - 
Executable Documents
 
Dear Colleagues

This is a reminder  for this week;s very interesting Scientific Discourse 
concall scheduled Mon., 20 Jun 2011, at 10am EDT 

The topic is Executable Documents - our speaker is Anita De Waard who will 
present on the results of Elsevier's recently concluded "Executable Document" 
Grand Challenge. 

Dial-in & IRC Information

*       Dial-In #: +1.617.761.6200 (Cambridge, MA)
*       Dial-In #: +33.4.26.46.79.03 (Paris, France)
*       Dial-In #: +44.203.318.0479 (London, UK)
*       Participant Access Code: 42572 ("HCLS2")
*       IRC Channel: irc.w3.org <http://irc.w3.org/>  port 6665 channel #HCLS2 
use IRC direct link 
<http://www.mibbit.com/chat/?server=irc.w3.org:6665&channel=%23hcls2>  or (see 
W3C IRC page <http://www.w3.org/Project/IRC/>  for details, or see Web IRC 
<http://cgi.w3.org/member-bin/irc/irc.cgi> )
*       Mibbit quick start: Click on mibbit for instant IRC access
*       Duration: 1hr


Best

Tim




The information in this e-mail is intended only for the person to whom it is
addressed. If you believe this e-mail was sent to you in error and the e-mail
contains patient information, please contact the Partners Compliance HelpLine at
http://www.partners.org/complianceline . If the e-mail was sent to you in error
but does not contain patient information, please contact the sender and properly
dispose of the e-mail.

Elsevier B.V. Registered Office: Radarweg 29, 1043 NX Amsterdam, The 
Netherlands, Registration No. 33156677 (The Netherlands)


Reply via email to